Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization.
Anti-PD-1
Cetirizine
Drug repurposing
Malignant melanoma
Tumor-associated macrophage
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
30 09 2022
30 09 2022
Historique:
received:
14
09
2022
accepted:
16
09
2022
entrez:
30
9
2022
pubmed:
1
10
2022
medline:
5
10
2022
Statut:
epublish
Résumé
The clinical observation showed a potential additive effect of anti-PD-1 agents and cetirizine in patients with advanced melanoma. Clinical outcomes of concomitant cetirizine/anti-PD-1 treatment of patients with stage IIIb-IV melanoma were retrospectively collected, and a transcriptomic analysis was performed on blood samples obtained at baseline and after 3 months of treatment. Patients treated with cetirizine concomitantly with an anti-PD-1 agent had significantly longer progression-free survival (PFS; mean PFS: 28 vs 15 months, HR 0.46, 95% CI: 0.28-0.76; p = 0.0023) and OS (mean OS was 36 vs 23 months, HR 0.48, 95% CI: 0.29-0.78; p = 0.0032) in comparison with those not receiving cetirizine. The concomitant treatment was significantly associated with ORR and DCR (p < 0.05). The expression of FCGR1A/CD64, a specific marker of macrophages, was increased after the treatment in comparison with baseline in blood samples from patients receiving cetirizine, but not in those receiving only the anti-PD1, and positively correlated with the expression of genes linked to the interferon pathway such as CCL8 (rho = 0.32; p = 0.0111), IFIT1 (rho = 0.29; p = 0.0229), IFIT3 (rho = 0.57; p < 0.0001), IFI27 (rho = 0.42; p = 0.008), MX1 (rho = 0.26; p = 0.0383) and RSAD2 (rho = 0.43; p = 0.0005). This retrospective study suggests that M1 macrophage polarization may be induced by cetirizine through the interferon-gamma pathway. This effect may synergize with the immunotherapy of advanced melanoma with anti-PD-1 agents.
Sections du résumé
BACKGROUND
The clinical observation showed a potential additive effect of anti-PD-1 agents and cetirizine in patients with advanced melanoma.
METHODS
Clinical outcomes of concomitant cetirizine/anti-PD-1 treatment of patients with stage IIIb-IV melanoma were retrospectively collected, and a transcriptomic analysis was performed on blood samples obtained at baseline and after 3 months of treatment.
RESULTS
Patients treated with cetirizine concomitantly with an anti-PD-1 agent had significantly longer progression-free survival (PFS; mean PFS: 28 vs 15 months, HR 0.46, 95% CI: 0.28-0.76; p = 0.0023) and OS (mean OS was 36 vs 23 months, HR 0.48, 95% CI: 0.29-0.78; p = 0.0032) in comparison with those not receiving cetirizine. The concomitant treatment was significantly associated with ORR and DCR (p < 0.05). The expression of FCGR1A/CD64, a specific marker of macrophages, was increased after the treatment in comparison with baseline in blood samples from patients receiving cetirizine, but not in those receiving only the anti-PD1, and positively correlated with the expression of genes linked to the interferon pathway such as CCL8 (rho = 0.32; p = 0.0111), IFIT1 (rho = 0.29; p = 0.0229), IFIT3 (rho = 0.57; p < 0.0001), IFI27 (rho = 0.42; p = 0.008), MX1 (rho = 0.26; p = 0.0383) and RSAD2 (rho = 0.43; p = 0.0005).
CONCLUSIONS
This retrospective study suggests that M1 macrophage polarization may be induced by cetirizine through the interferon-gamma pathway. This effect may synergize with the immunotherapy of advanced melanoma with anti-PD-1 agents.
Identifiants
pubmed: 36180872
doi: 10.1186/s12967-022-03643-w
pii: 10.1186/s12967-022-03643-w
pmc: PMC9523893
doi:
Substances chimiques
Programmed Cell Death 1 Receptor
0
Interferon-gamma
82115-62-6
Cetirizine
YO7261ME24
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
436Informations de copyright
© 2022. The Author(s).
Références
Cancer Res. 2016 Apr 15;76(8):2105-14
pubmed: 26921339
Anticancer Res. 2021 Dec;41(12):5913-5918
pubmed: 34848445
Lancet Oncol. 2019 Sep;20(9):1239-1251
pubmed: 31345627
Turk J Pediatr. 2005 Apr-Jun;47(2):111-5
pubmed: 16052848
F1000Prime Rep. 2014 Mar 03;6:13
pubmed: 24669294
Proc Natl Acad Sci U S A. 1983 Jun;80(12):3782-6
pubmed: 6407020
Lancet. 2021 Sep 11;398(10304):1002-1014
pubmed: 34509219
Nat Med. 2013 Oct;19(10):1264-72
pubmed: 24056773
Anticancer Drugs. 2020 Nov;31(10):989-996
pubmed: 32694422
Clin Cancer Res. 2021 Jan 1;27(1):87-95
pubmed: 33127652
J Clin Oncol. 2022 Jan 10;40(2):127-137
pubmed: 34818112
N Engl J Med. 2015 Sep 24;373(13):1270-1
pubmed: 26398076
Front Immunol. 2017 Oct 26;8:1383
pubmed: 29123526
Biomed Pharmacother. 2022 Feb;146:112588
pubmed: 35062062
Hum Pathol. 2016 Jun;52:136-44
pubmed: 26980050
Front Microbiol. 2022 Jan 11;12:803427
pubmed: 35087503
Nanoscale. 2022 Feb 10;14(6):2304-2315
pubmed: 35083479
Cells. 2022 Feb 07;11(3):
pubmed: 35159385
Front Oncol. 2021 Jan 19;10:587422
pubmed: 33542899
Cell Rep. 2018 Oct 2;25(1):95-106.e6
pubmed: 30282041
Curr Med Chem. 2021;28(11):2175-2194
pubmed: 33109032